Year: 2024

MERGER UPDATE AND RESULTS OF GENERAL MEETINGS Albion Enterprise VCT PLC (AAEV)                       (LEI: 213800OVSRDHRJBMO720) Albion Development VCT PLC (AADV)                  (LEI: 213800FDDMBD9QLHLB38) Albion Technology & General VCT PLC (AATG)   (LEI: 213800TKJUY376H3KN16) Albion KAY VCT PLC (KAY)                                    (LEI:213800DK8H27QY3J5R45) Albion Crown VCT PLC (CRWN)                            (LEI: 213800SYIQPA3L3T1Q68) Albion Venture Capital Trust PLC (AAVC)            (LEI: 213800JKELS32V2OK421) (together the Companies and each a Company) 11 December 2024 On 12 November 2024, the Companies issued a joint circular (Circular) setting out proposals for, amongst other things, merging the six Companies into three (Mergers), offers for subscription by AAEV, AATG and CRWN (as the proposed acquiring Companies),...

Albion Enterprise VCT PLC (AAEV)                          (LEI: 213800OVSRDHRJBMO720) Albion Development VCT PLC (AADV)                     (LEI: 213800FDDMBD9QLHLB38) Albion Technology & General VCT PLC (AATG)      (LEI: 213800TKJUY376H3KN16) Albion KAY VCT PLC (KAY)                                        (LEI:213800DK8H27QY3J5R45) Albion Crown VCT PLC (CRWN)                                (LEI: 213800SYIQPA3L3T1Q68) Albion Venture Capital Trust PLC (AAVC)                (LEI: 213800JKELS32V2OK421) (together the Companies and each a Company) 11 December 2024 On 12 November 2024, the Companies issued a joint circular (Circular) setting out proposals for, amongst other things, merging the six Companies into three (Mergers), offers for subscription by AAEV, AATG and CRWN (as the proposed acquiring Companies), revised fee arrangements...

Albion Enterprise VCT PLC (AAEV)                         (LEI: 213800OVSRDHRJBMO720) Albion Development VCT PLC (AADV)                    (LEI: 213800FDDMBD9QLHLB38) Albion Technology & General VCT PLC (AATG)     (LEI: 213800TKJUY376H3KN16) Albion KAY VCT PLC (KAY)                                      (LEI:213800DK8H27QY3J5R45) Albion Crown VCT PLC (CRWN)                              (LEI: 213800SYIQPA3L3T1Q68) Albion Venture Capital Trust PLC (AAVC)               (LEI: 213800JKELS32V2OK421) (together the Companies and each a Company) 11 December 2024 On 12 November 2024, the Companies issued a joint circular (Circular) setting out proposals for, amongst other things, merging the six Companies into three (Mergers), offers for subscription by AAEV, AATG and CRWN (as the proposed acquiring Companies), revised fee arrangements that would...

Please be informed that, at the initiative of UAB “Orkela” (company code 304099538, registered address at Jogailos St. 4, Vilnius, Lithuania) (the Company) and by the decision of the bondholder’s representative UAB “AUDIFINA” (company code 125921757, registered address at A. Juozapavičiaus st. 6, Vilnius, Lithuania) (the Trustee), a meeting of the bondholders of the Company’s bond issue, ISIN code LT0000405961 (the Bonds), will be held on 9 January 2025 at 10:00 AM (the Meeting). The venue of the Meeting will be announced to the Bondholders separately. The Company initiated the convening of the Meeting because it is still negotiating the refinancing terms of the Bonds with the bank. Therefore, it expects to receive approval from the Bondholders to extend the redemption date of the Bonds by 6 months, from the originally...

Currently enrolling randomized, double-blind, placebo-controlled, dose-finding, Phase 2 clinical trial to evaluate the safety and efficacy of KDS2010 in patients with Alzheimer’s disease with mild cognitive impairment and mild dementia is currently recruiting in South Korea in 114 patients and U.S. cohort will be added in 2025. KDS2010 (Tisolagiline) is a new reversible selective monoamine oxidase B (MAO-B) inhibitor being studied for its potential in treating neurodegenerative diseases like Alzheimer’s disease. Apart from its role as a MAO-B inhibitor, it also influences astrocytic GABA inhibition. In neurodegenerative diseases like Alzheimer’s, altered GABAergic activity and dysfunction in astrocytic regulation of neurotransmitter systems contribute to cognitive decline and neuroinflammation. A highly selective and reversible...

DHA Omega-3 Supplements from CanolaHealth Canada has Approved Nutriterra DHA Canola as an ingredient in dietary supplementsWEST SACRAMENTO, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — Nutriterra® Total Omega-3 has received Health Canada approval as an ingredient in dietary supplements. Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) issued a product license, Natural Product Number (NPN) 80136254, which authorizes it to be marketed and sold as a novel, canola-based total omega-3 oil with the following health claims:Supports heart health and cardiovascular function Supports normal brain function Source of docosahexaenoic acid (DHA) for maintaining good health Source of alpha-linolenic acid (ALA) for maintaining good health Source of an essential fatty acid for the maintenance of good health Source...

PRESS RELEASEIvry-sur-Seine, France — December 11, 2024, 18h45 CEST THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT PERMITTED IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE THE RELEVANT APPLICABLE REGULATION VOLUNTARY PUBLIC TENDER AND EXCHANGE OFFER FOR ALL THE SHARES OF UNIEURO PRELIMINARY RESULTS OF THE PROCEDURE TO COMPLY WITH THE OBLIGATION TO PURCHASE UNDER ART. 108, PAR. 2, OF THE CFA 96.70% OF THE SHARE CAPITAL OF UNIEURO SUCCESFULLY REACHED (INCLUDING TREASURY SHARES)Preliminary results of the Procedure to Comply with the Obligation to Purchase under Art. 108, Par. 2, of the CFA: 3.04% of Unieuro’s share capital tendered, which cumulated with the 93.32% already owned by the Offerors...

Mercury’s DRF2270 system-on-module, featuring Altera’s latest Agilex 9 FPGA.Mercury’s DRF2270 system-on-module, featuring Altera’s latest Agilex 9 FPGA.ANDOVER, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing power to the edge, today introduced a system-on-module (SOM) and 3U SOSA-aligned OpenVPX board powered by Altera’s™ most advanced Agilex 9 Direct RF FPGA chips. The DRF2270 SOM and DRF5270 3U board are the latest additions to Mercury’s portfolio of Direct RF digital signal processing products that use Altera FPGAs to detect and process information from a wide portion of the electromagnetic spectrum. These commercially available products directly digitize radio frequency signals at the antenna, eliminating...

Press Release Regulated information Solvac announces a second interim dividend for the financial year 2024 to be paid on January 30, 2025 Solvac will announce on March 7, 2025, the interim dividend equivalent to the balance ex-2024 As announced on August 2, 2024, Solvac confirms its policy of distributing almost all the dividends received from Solvay and Syensqo after deducting its costs and financial expenses. As a reminder, Solvac paid on August 27, 2024 a first interim dividend for the 2024 financial year of €3.486 gross per share. The Board of Directors has decided today the payment of a second interim dividend ex-2024 of €1.48 gross per share. This payment will be made on Thursday January 30, 2025. The Board of Directors also decided that the interim dividend equivalent to the balance ex-2024 will be announced on March 7, 2025, along...